VP of People Operations - Juno Therapeutics

VP of People Operations - Juno Therapeutics

August 17, 2017
August 17, 2017

Job Summary


Established in 2013, Juno Therapeutics is on a quest to radically change the course of medicine.  Using a cancer patient’s own T cells, Juno’s investigational treatments harness the power of a patient’s own immune system to treat cancer and other serious diseases. 

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. Raising one of the largest Series A investments in biotech history, with total investments of $310m, Juno made an initial public offering in December 2014.

In preparation for the anticipated commercialization of their CAR-T therapy in 2018, Juno has grown to 600 employees, and will hire another 400 in the next year, doubling over that again in the next two years. 


As the COO of the People team, you will own and lead operations to include systems/tools/automation, people and recruiting operations, training & development, employee experience and analytics.  The best candidate for the role will be obsessed with staying one step ahead of making life at Juno productive, engaging, friction-free, so employees can focus on curing cancer! 

Quick Facts

Alternate Location:San Francisco
Job Family:Human Resources
Years of Experience:15+
Reporting to:SVP, People
Company Founded:2013
Company IPO:2014
Current # Employees:600
Planned # Employees:2000

More Info


Juno Therapeutics
Hans Bishop
Business Executive, CEO
Herd Freed Hartz
Company, Executive Search Firm
City in Washington

Photos - Company Photos22

Juno Therapeutics

Juno Therapeutics is a biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs.[2] The company raised $300 million through private funding and a further $265 million through their IPO.


Biotechnology is the use of living systems and organisms to develop or make products, or "any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use" (UN Convention on Biological Diversity, Art. 2).[1] Depending on the tools and applications, it often overlaps with the (related) fields of bioengineering, biomedical engineering, biomanufacturing, molecular engineering, etc.

For thousands of years, humankind has used biotechnology in agriculture, food production, and medicine.[2] The term is largely believed to have been coined in 1919 by Hungarian engineer Károly Ereky. In the late 20th and early 21st centuries, biotechnology has expanded to include new and diverse sciences such as genomics, recombinant gene techniques, applied immunology, and development of pharmaceutical therapies and diagnostic tests.[2]

Job Documents2


Company Info - Targeted Diseases6

Company Info - Therapies5

Company Info - Key Partners7


News Articles9

Editas Medicine Announces Third Quarter 2017 Results and Update
  –  November 7, 2017
Nov. 07, 2017 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today reported financial results for the third quarter ... pursuant to our collaboration with Juno Therapeutics, Inc., partially offset by a $0.4 ...
3 Reasons It's Smart to Buy Celgene's Stock Now
  –  November 3, 2017
Updated results from a multicenter study of bb2121 anti-BCMA CAR T cell therapy (Oral Abstract #740), and the presentation, will be on Monday, December 11 at 3:00 p.m. EST. The abstract for Juno Therapeutics' and Celgene's JCAR017, a second-generation CAR ...
Juno Therapeutics' 3rd Quarter Boosted by Potential Rival Novartis
  –  November 2, 2017
Juno Therapeutics (NASDAQ: JUNO) stock has soared so far in 2017, partially due to its own good fortunes, but also moving upwards as other CAR-T developers have experienced success. Juno announced its third-quarter results after the market closed on Wednesday.
Juno Therapeutics' (JUNO) CEO Hans Bishop on Q3 2017 Results - Earnings Call Transcript
  –  November 2, 2017
Good day ladies and gentlemen, and welcome to the Juno Therapeutics 2017 Third Quarter Financial Results Conference Call ... that have failed first-line therapy and need better treatments. Our pipeline covers all of these indications, and we arrived ...
Juno Therapeutics to Highlight New Advances in CD19- and BCMA-Targeted CAR T Therapy at ASH
  –  November 1, 2017
Juno Therapeutics ... showcase promising data coming from our pipeline of CD19- and BMCA-directed CAR T cell product candidates,” said Sunil Agarwal, M.D., Juno's President of Research and Development. "Results from the ongoing TRANSCEND study of ...
Transdermal Drug Delivery Devices - Medical Devices Pipeline Assessment, 2017
  –  October 12, 2017
31 oct 2017 Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2017 Financial Results on November 13 ... Kyros Law is Investigating Legal Claims on Behalf of JUNO THERAPEUTICS, INC. (NASDAQ: JUNO) Investors BOSTON, Oct. 31, 2017 ...
Juno Therapeutics : Opens New Headquarters and Research Center
  –  September 21, 2017
Juno Therapeutics, Inc. (NASDAQ ... and the promise of Juno’s product candidate pipeline. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements ...
Global CAR T-cell Therapy for Multiple Myeloma Pipeline Analysis Report 2017
  –  November 3, 2017
The "CAR T-cell Therapy for Multiple Myeloma - A Pipeline Analysis Report" report has been added ... 12,590 deaths occur due to this disease in the US. Major companies Juno Therapeutics Kite Pharma Novartis Collectis Key Topics Covered: Part 01: Executive ...
Juno Therapeutics Inc (JUNO): 3 Reasons to Be Bullish
  –  September 27, 2017
Juno Therapeutics Inc (NASDAQ:JUNO), which is a biotech operator ... Something else to keep in mind: Juno has a robust pipeline. Note that the company has nine drugs in different trials (they range from Phase 1 to Phase 2). Right now, the lead candidate ...

Related News Coverage


Featured Locations5